VACCINE TYPE

• Dengvaxia^®, or the Dengue Tetravalent Vaccine[10][9]
  • IMPORTANT NOTE: Sanofi-Pasteur will stop manufacturing Dengvaxia^® in 2026 given a lack of demand in the global market.
  • Approved by the FDA for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection AND living in dengue-endemic areas[11].
    • ACIP recommends using this vaccine for individuals aged 9 to 16 WITH evidence of a previous dengue infection AND living in areas where dengue is endemic[6].
    • WHO recommends using this vaccine for individuals aged 9 to 45 years or 9 to 60 years (depending on the country-specific regulatory approvals) with laboratory-confirmed previous dengue infection AND living in dengue-endemic areas[12]
  • It is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3, and 4.
    • The vaccine is built on a yellow fever backbone component.
    • 3-dose series.
• Qdenga^® [7][2]
  • Not currently FDA approved but approved in 40 other countries for use in individuals aged 6 to 16 years living in dengue-endemic areas OR in individuals aged 6 to 60 years with comorbidities living in dengue-endemic areas.
  • It is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3, and 4.
    • The vaccine uses the DENV2 strain as the genomic backbone.
    • 2-dose series.
• Butantan-Dengue Vaccine[3][1]
  • Currently under development and not approved in any country. The company submitted approval in Brazil in December 2024.
  • It is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3, and 4.
    • 1-dose series.